Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
6.50
Nov 17 • 3:59 PM ET Dollar change+0.10 Percentage change(1.56%)
Aftermarket Close
6.50
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
66.23M
Enterprise Value
106.54M
Income
-14.61M
Sales
3.96M
Book/sh
-3.72
Cash/sh
0.97
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
14
IPO
Oct 16, 2014
P/E
-
Forward P/E
6.48
PEG
-
P/S
16.72
P/B
-
P/C
6.68
P/FCF
-
EV/EBITDA
-
EV/Sales
26.90
Quick Ratio
1.72
Current Ratio
1.72
Debt/Eq
-
LT Debt/Eq
-
Option/Short
No / Yes
EPS (ttm)
-1.23
EPS next Y
1.00
EPS next Q
-0.04
EPS this Y
-122.05%
EPS next Y
277.09%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
23.85% -
EPS Y/Y TTM
-155.19%
Sales Y/Y TTM
-97.39%
EPS Q/Q
54.16%
Sales Q/Q
-64.55%
Insider Own
30.97%
Insider Trans
2.98%
Inst Own
46.81%
Inst Trans
-0.46%
ROA
-59.93%
ROE
-
ROIC
-144.12%
Gross Margin
82.75%
Oper. Margin
-358.39%
Profit Margin
-368.58%
SMA20
-20.31%
SMA50
-26.14%
SMA200
-17.16%
Trades
Shs Outstand
10.19M
Shs Float
7.03M
52W High
19.15 -66.05%
52W Low
3.92 65.82%
Volatility
9.38% 7.18%
ATR (14)
0.67
RSI (14)
29.41
Beta
0.37
Rel Volume
1.97
Avg Volume
36.47K
Volume
71,661
Perf Week
-19.75%
Perf Month
-27.46%
Perf Quarter
-32.29%
Perf Half Y
-30.92%
Perf YTD
-64.07%
Perf Year
-50.38%
Perf 3Y
-49.02%
Perf 5Y
-98.54%
Perf 10Y
-98.58%
Prev Close
6.40
Price
6.50
Change %
1.56%
Consensus
Buy
Avg. Price Target
$13.67
Implied Upside
+110.3%
Analysts9incl. previous ratings
Rating Distribution1 Buy · 6 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 08, 2026Upgrade
CCanaccord Genuity
Hold → Buy$13+100.0%
Jan 13, 2026Downgrade
CCanaccord Genuity
Buy → Hold$6-7.7%
Nov 09, 2023Downgrade
MFG logoMMizuho
Buy → Neutral$31 → $1-84.6%
Nov 09, 2023Downgrade
HH.C. Wainwright
Buy → Neutral
Nov 09, 2023Downgrade
EVR logoEEvercore ISI
Outperform → In-line
Jul 20, 2022Downgrade
C logoCCitigroup
Neutral → Sell$8 → $3-53.8%
Jul 13, 2022Downgrade
SF logoSStifel
Buy → Hold$16 → $5-23.1%
Jul 13, 2022Downgrade
JPM logoJJP Morgan
Overweight → Neutral$10+53.8%
May 10, 2022Downgrade
C logoCCitigroup
Buy → Neutral$15 → $8+23.1%
May 13, 2021Upgrade
JPM logoJJP Morgan
Neutral → Overweight$23 → $29+346.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Nguyen AnhCoDirectorNov 16 '26Proposed Sale8.235,98149,224Nov 16 05:13 PM
Cherry Brian NDirectorSep 04 '26Buy9.60104,166999,994166,486Sep 04 06:20 PM
Nguyen AnhCoDirectorAug 17 '26Proposed Sale8.365,06242,318Aug 26 07:47 PM
Nguyen AnhCoPresident and CEOAug 17 '26Sale8.085,06240,883132,775Aug 26 07:45 PM
Nguyen AnhCoPresident and CEOMay 18 '26Sale9.135,24147,845137,837May 20 05:24 PM
Grant-Huerta YaninaChief Accounting OfficerMay 18 '26Sale9.132,41422,03649,636May 20 05:24 PM
Nguyen AnhCoDirectorMay 18 '26Proposed Sale10.485,98162,681May 18 04:45 PM
Grant-Huerta YaninaOfficerMay 18 '26Proposed Sale10.482,75428,862May 18 04:44 PM
Panacea Innovation Ltd10% OwnerMay 07 '26Sale10.10313,4463,165,0211,011,000May 11 06:45 PM
EcoR1 Capital, LLC10% OwnerMay 07 '26Buy9.35507,4074,744,2551,552,000May 11 05:34 PM
Panacea Innovation Ltd10% OwnerMay 07 '26Proposed Sale10.10313,4463,165,021May 07 08:30 PM
Panacea Innovation Ltd10% OwnerMar 17 '26Option Exercise0.00259,16326307,899Mar 19 04:30 PM
Grant-Huerta YaninaChief Accounting OfficerMar 02 '26Sale5.082,10410,69131,750Mar 04 04:28 PM
Nguyen AnhCoPresident and CEOMar 02 '26Sale5.092,99615,23761,978Mar 04 04:28 PM
Nguyen AnhCoDirectorMar 02 '26Proposed Sale5.423,35518,184Mar 02 06:25 PM
Grant-Huerta YaninaOfficerMar 02 '26Proposed Sale5.422,35512,764Mar 02 06:24 PM
Panacea Innovation Ltd10% OwnerJan 12 '26Sale6.0780,554489,0191,324,446Jan 14 09:16 PM
Panacea Innovation Ltd10% OwnerJan 12 '26Proposed Sale5.8840,000235,200Jan 12 09:26 PM
Panacea Innovation Ltd10% OwnerNov 28 '25Option Exercise0.0048,737548,737Dec 01 05:00 PM
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
PresidentDr. Anhco Nguyen Ph.D.
Interim Chief Financial OfficerMr. Kevin G. Sarney CPA
Senior Vice President of Regulatory AffairsMr. Jim Sesic